Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old m...

Full description

Bibliographic Details
Main Authors: Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
RET intergenic fusion
pralsetinib
lung adenocarcinoma
novel intergenic
tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.929763/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.929763/full

Similar Items